Medigen Biotechnology (ROCO:3176) Long-Term Debt : NT$411 Mil (As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Long-Term Debt?

Medigen Biotechnology's Long-Term Debt for the quarter that ended in Dec. 2024 was NT$411 Mil.

Medigen Biotechnology's quarterly Long-Term Debt increased from Jun. 2024 (NT$369 Mil) to Sep. 2024 (NT$421 Mil) but then declined from Sep. 2024 (NT$421 Mil) to Dec. 2024 (NT$411 Mil).

Medigen Biotechnology's annual Long-Term Debt declined from Dec. 2022 (NT$2,129 Mil) to Dec. 2023 (NT$449 Mil) and declined from Dec. 2023 (NT$449 Mil) to Dec. 2024 (NT$411 Mil).

Medigen Biotechnology Long-Term Debt Historical Data

The historical data trend for Medigen Biotechnology's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Long-Term Debt Chart

Medigen Biotechnology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

486.37

470.77

2,129.16

449.10

411.25

Medigen Biotechnology Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															449.10	445.71	369.14	420.61	411.25

Medigen Biotechnology (ROCO:3176) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Medigen Biotechnology Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigen Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560

Website

https://www.medigen.com.tw

Medigen Biotechnology Corp is a biopharmaceutical company engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The company has four segments: Nucleic acid department: segment, which derives maximum revenue, is responsible for services of testing reagents, instruments and inspection on behalf of others; New drug and vaccine research and development segment: responsible for the development and relevant services of new drugs and vaccine; Cytotherapy department: responsible for research and development and relevant services of cytotherapy; and Generic drug, aesthetic medicine product and dietary supplement segment is responsible for production and sales and relevant services of western medicine, aesthetic medicine product and dietary supplement.

Medigen Biotechnology Headlines

No Headlines